Number of shares and votes in BioArctic AB (publ) as of November 30, 2022 November 30, 2022 18:00 Regulatory Read more
BioArctic’s partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer’s disease at CTAD conference November 30, 2022 01:50 Regulatory Read more
Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s disease published in the New England Journal of Medicine November 30, 2022 01:50 Regulatory Read more
BioArctic’s founders intend to divest minor part of their shareholding October 25, 2022 17:35 Regulatory Read more
Lecanemab phase 3 Clarity AD study in early Alzheimer’s disease meets primary and all key secondary endpoints with high statistical significance September 28, 2022 01:30 Regulatory Read more
The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alzheimer’s disease under the accelerated approval pathway July 6, 2022 01:30 Regulatory Read more
Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer’s disease under the accelerated approval pathway May 10, 2022 01:35 Regulatory Read more
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio April 20, 2022 07:50 Regulatory Read more
The Nomination Committee’s proposal for the election of board members in BioArctic AB March 9, 2022 08:00 Regulatory Read more
Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval March 4, 2022 00:46 Regulatory Read more
